Artelo Biosciences, Inc. (ARTL)

Artelo Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	2.82	6.89	6.63	2.14	4.42
Short-Term Investments	7.61	10.65	3.44	0	0
Cash & Cash Equivalents	10.43	17.53	10.07	2.14	4.42
Cash Growth	-40.53%	74.20%	369.89%	-51.58%	1205.30%
Other Current Assets	0.55	0.79	0.25	0.2	0.02
Total Current Assets	10.98	18.32	10.32	2.34	4.44
Property, Plant & Equipment	0.02	0.06	0.09	0	0
Goodwill and Intangibles	2.04	2.04	2.04	2.04	2.04
Other Long-Term Assets	0	0	0.19	0	0
Total Long-Term Assets	2.06	2.1	2.32	2.04	2.04
Total Assets	13.04	20.42	12.64	4.38	6.48
Accounts Payable	1.27	0.96	0.5	0.5	0.35
Current Debt	0.02	0.04	0.03	0	0
Other Current Liabilities	0	0	0	0	0.67
Total Current Liabilities	1.29	1	0.53	0.5	1.02
Long-Term Debt	0	0.02	0.07	0	0
Total Long-Term Liabilities	0	0.02	0.07	0	0
Total Liabilities	1.29	1.02	0.59	0.5	1.02
Total Debt	0.02	0.06	0.1	0	0
Debt Growth	-63.49%	-33.68%	-	-	-
Retained Earnings	-40.31	-31.02	-16.9	-9.47	-4.81
Comprehensive Income	-0.2	-0.25	0.02	0.06	-0.01
Shareholders' Equity	11.75	19.4	12.04	3.88	5.46
Net Cash / Debt	10.4	17.47	9.97	2.14	4.42
Net Cash / Debt Growth	-40.45%	75.23%	365.45%	-51.58%	1205.30%
Net Cash Per Share	3.51	6.17	8.01	8.67	30.55
Working Capital	9.69	17.32	9.79	1.84	3.42
Book Value Per Share	3.97	6.85	9.67	15.68	37.71

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).